RxDoctor Payments Data

Armen Derboghossians, MD

Urology · Glendale, CANPI 1558641852

Payments from drug & device makers

$2,259in general payments, 2019–2025

Across 96 payments — averaging $23.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$801
  • Sumitomo Pharma America, Inc.$739
  • AbbVie$134
  • Johnson & Johnson$131
  • Procept Biorobotics Corporation$94
  • Caldera Medical, Inc$87
  • plus $274 from 7 others

What the payments were for

  • Food & beverage$2,04490%
  • Education$21510%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,259 in reported general payments places this provider in the 45th percentile of 1,324 urology providers in California.

See all urology providers in California

Medicare billing

Part B allowed, 2024
$676,748
Medicare patients
1,126
Services billed
4,119

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron2,363$1,257,984
XtandiEnzalutamide34$462,812
MyrbetriqMirabegron419$207,178
Fesoterodine Fumarate ErFesoterodine Fumarate223$16,620
Tadalafil99$15,990
Tamsulosin Hcl2,111$13,096
CialisTadalafil25$11,621
Mirabegron ErMirabegron29$9,946
FlomaxTamsulosin Hcl11$6,314
Tolterodine Tartrate ErTolterodine Tartrate120$5,757
PremarinEstrogens, Conjugated13$5,677
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip209$3,713
Dutasteride134$3,680
Solifenacin Succinate93$1,632
Silodosin41$1,583

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$739$1,257,9842,363 claims
Astellas Pharma US IncXtandi, Myrbetriq$801$669,989453 claims
PfizerPremarin$55$5,67713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,324 urology providers in California.

Other urology in Glendale

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →